HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Academic Article uri icon

Overview

abstract

  • Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.

publication date

  • October 29, 2015

Research

keywords

  • Lung Neoplasms
  • Mutagenesis, Insertional
  • Receptor, ErbB-2

Identity

PubMed Central ID

  • PMC4724317

Scopus Document Identifier

  • 84949191376

Digital Object Identifier (DOI)

  • 10.1016/j.lungcan.2015.10.025

PubMed ID

  • 26559459

Additional Document Info

volume

  • 90

issue

  • 3